GlassScriptPhysician profile
William K Graham
NPI 1942228028
$4,043.14
in general payments reported to CMS, 2019-2025
17 companies · $789 in 2025
The $789 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,353 · 2020: $48.72 · 2021: $76.99 · 2022: $216 · 2023: $976 · 2024: $584 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,580 · Travel and Lodging: $524 · Education: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,580.01 |
| Travel and Lodging | $523.63 |
| Education | $245.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,296.07 | 2022-2025 | Inspire |
| Olympus Corporation of The Americas | $1,010.66 | 2019 | |
| Philips North America LLC | $444.48 | 2023-2025 | Encore, (8874) Incourage, Vest Therapy Und |
| Sunovion Pharmaceuticals INC. | $340.48 | 2019-2021 | |
| Harmony Biosciences LLC | $273.06 | 2024-2025 | |
| Mylan Specialty L.P. | $187.40 | 2022-2024 | Yupelri, Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.22 | 2019-2025 | Ofev |
| Regeneron Healthcare Solutions, INC. | $73.40 | 2024-2025 | Dupixent |
| Viatris Specialty LLC | $63.61 | 2025 | Yupelri |
| Glaxosmithkline, LLC. | $59.08 | 2024 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $41.04 | 2024-2025 | Fasenra |
| Genentech USA, INC. | $38.00 | 2019 | |
| Jazz Pharmaceuticals INC. | $28.59 | 2025 | |
| Axsome Therapeutics, INC. | $21.14 | 2025 | Sunosi |
| Lilly USA, LLC | $19.57 | 2025 | Zepbound |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $17.99 | 2022 | |
| Celgene Corporation | $14.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.